Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 4/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | RHOA | P61586 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.36 |
| ▸ | RAF1 | P04049 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.36 |
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.36 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.35 |
| ▸ | CASR | P41180 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776361 | 0.89 | BRAF (0.44) | BRAFCREBBPBRD4RHOAFYN | |
| SCHEMBL16776374 | 0.86 | TSHR (0.46) | BRAFTP53GAASMN1; SMN2POLB | |
| SCHEMBL16776371 | 0.83 | BRAF (0.38) | BRAFCREBBPBRD4TP53GAA | |
| SCHEMBL19699055 | 0.80 | CREBBP (0.42) | BRAFCREBBPBRD4RHOACNR1 | |
| SCHEMBL16776357 | 0.80 | BRAF (0.40) | BRAFRHOA | |
| SCHEMBL16776372 | 0.79 | CNR2 (0.51) | TP53GAASMN1; SMN2 | |
| SCHEMBL16776375 | 0.79 | FAAH (0.38) | BRAFTP53GAASMN1; SMN2 | |
| SCHEMBL16776024 | 0.78 | IMPDH2 (0.46) | BRAFCREBBPBRD4RHOACNR1 | |
| SCHEMBL16776381 | 0.77 | ABL1 (0.36) | SMN1; SMN2POLBMAPT | |
| SCHEMBL16776379 | 0.77 | WNT1 (0.39) | BRAFCREBBPBRD4RHOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | BRAF 3419/4885CREBBP 528/4885BRD4 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.